Clinical Evaluation Of Roxadustat Capsule In The Treatment Of Renal Anemia In Maintenance Hemodialysis Patients

Objective: To investigate the clinical efficacy of Roxadustat in the treatment of renal anemia in MHD patients with chronic renal failure,in order to provide clinical reference for the treatment of renal anemia in patients with chronic renal failure.Methods: This study was a randomized controlled study.64 patients with renal anemia were treated with MHD for more than 3 months and stable dose of recombinant human erythropoietin(r Hu EPO)for more than 6 weeks in the hemodialysis center of the Fifth affiliated Hospital of Xinjiang Medical University from January 2020 to October 2020.According to the method of random number table,according to the proportion of 1:1,they were divided into test group(n=32)and control group(n=32).The experimental group was treated with Roxadustat capsule combined with polysaccharide iron complex capsule,while the control group was treated with traditional(r Hu EPO)combined with polysaccharide iron complex capsule.T-test and repeated measurement analysis of variance were used to compare the changes of anemia,iron metabolism,blood lipids and microinflammatory factors before treatment and 8 weeks and 12 weeks after treatment between the two groups,and the adverse reactions were recorded.Results: There was no significant difference in the characteristic indexes of general data between the two groups(P>0.05).Compared with those before observation,Hb,Hct,Fe,SF and TSAT in the two groups increased and showed an upward trend after 8 and 12 weeks of observation,while TC,TG,LDL,CRP and IL-6 in the test group decreased and showed a downward trend(P<0.05);HDL,while there was no obvious discrimination in TC,TG,LDL,HDL,CRP and IL-6 in the r Hu EPO group.The levels of Hb,Hct,Fe,SF,TSAT,TC,TG,LDL,CRP and IL-6 were different between the two groups,especially in the experimental group.After 8 and 12 weeks of drug intervention,the Hb,Hct,Fe,SF and TSAT in the experimental group were higher than those in the control group at the same time,while the levels of TC,TG,LDL,CRP and IL-6 in the Roxadustat group were lower than those in the another group at the same time(P<0.05).There was no significant difference in HDL at the same time(P>0.05).Conclusion: Compared with the traditional regimen for the treatment of renal anemia(r Hu EPO),Roxadustat can significantly improve anemia,iron metabolism,lipid metabolism and reduce microinflammation in vivo.It is speculated that it may reduce the incidence of cardio-cerebrovascular events and has better efficacy and safety.It has great popularizing significance and application value in clinical treatment.